Table 2.
Echocardiographic diagnosis | Benazepril (n = 77) | Placebo (n = 74) | P value |
---|---|---|---|
Hypertrophic cardiomyopathy | 28 | 33 | .32 |
Hypertrophic obstructive cardiomyopathy | 12 | 19 | .16 |
Restrictive cardiomyopathy | 10 | 4 | .16 |
Unclassified cardiomyopathy | 8 | 6 | .78 |
Dilated cardiomyopathy | 4 | 7 | .36 |
Mitral valve dysplasia | 4 | 1 | .37 |
Aortic stenosisa | 3 | 0 | .25 |
Ventricular septal defect plus mitral or tricuspid valve dysplasia | 3 | 0 | .25 |
Ventricular septal defect | 2 | 2 | 1.0 |
Atrial septal defect | 1 | 0 | 1.0 |
Mitral valve regurgitation | 1 | 0 | 1.0 |
Tricuspid valve insufficiency | 0 | 1 | .49 |
Not recorded | 1 | 1 | 1.0 |
Notes: Data are number of cases in each group at baseline. P values were calculated with Fisher's exact test.
One case of hypertrophic cardiomyopathy in the benazepril group had in addition aortic stenosis.